First Hawaiian Bank Sells 4,522 Shares of Hologic, Inc. (NASDAQ:HOLX)

First Hawaiian Bank lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,506 shares of the medical equipment provider's stock after selling 4,522 shares during the quarter. First Hawaiian Bank's holdings in Hologic were worth $772,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HOLX. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Smithfield Trust Co lifted its holdings in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in shares of Hologic in the fourth quarter worth $49,000. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HOLX has been the topic of a number of research reports. Raymond James reiterated an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Royal Bank of Canada reduced their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Trading Down 0.7%

HOLX stock traded down $0.47 during mid-day trading on Wednesday, reaching $62.57. 2,491,059 shares of the stock traded hands, compared to its average volume of 2,283,385. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The stock's fifty day moving average is $58.19 and its 200-day moving average is $65.65. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $13.94 billion, a P/E ratio of 19.74, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company posted $1.03 earnings per share. The firm's revenue was down 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.